Literature DB >> 11064262

Genetic and immunologic characterization of a novel serotype 4, 15 strain of Neisseria meningitidis.

M C Bash1, F Lynn, N F Concepcion, J W Tappero, G M Carlone, C E Frasch.   

Abstract

The porin proteins of Neisseria meningitidis are important components of outer membrane protein (OMP) vaccines. The class 3 porin gene, porB, of a novel serogroup B, serotype 4, 15 isolate from Chile (Ch501) was found to be VR1-4, VR2-15, VR3-15 and VR4-15 by porB variable region (VR) typing. Rabbit immunization studies using outer membrane vesicles revealed immunodominance of individual PorB (class 3) VR epitopes. The predominant anti-Ch501 PorB response was directed to the VR1 epitope. Anti-PorB VR1 mediated killing was suggested by the bactericidal activity of Ch501 anti-sera against a type 4 strain not expressing PorA or class 5 OMPs. Studies that examine the molecular epidemiology of individual porB VRs, and the immune responses to PorB epitopes, may contribute to the development of broadly protective group B meningococcal vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064262     DOI: 10.1111/j.1574-695X.2000.tb01519.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  3 in total

1.  Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic.

Authors:  Kristin H Dyet; Diana R Martin
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

2.  Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease.

Authors:  Moe H Kyaw; Stuart C Clarke; Peter Christie; Ian G Jones; Harry Campbell
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

3.  Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Authors:  Elisabeth Wedege; Betsy Kuipers; Karin Bolstad; Harry van Dijken; L Oddvar Frøholm; Clementien Vermont; Dominique A Caugant; Germie van den Dobbelsteen
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.